Julie Locklear

1.7k total citations · 1 hit paper
38 papers, 1.4k citations indexed

About

Julie Locklear is a scholar working on Psychiatry and Mental health, Experimental and Cognitive Psychology and Pharmacology. According to data from OpenAlex, Julie Locklear has authored 38 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Psychiatry and Mental health, 12 papers in Experimental and Cognitive Psychology and 8 papers in Pharmacology. Recurrent topics in Julie Locklear's work include Schizophrenia research and treatment (17 papers), Bipolar Disorder and Treatment (14 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (9 papers). Julie Locklear is often cited by papers focused on Schizophrenia research and treatment (17 papers), Bipolar Disorder and Treatment (14 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (9 papers). Julie Locklear collaborates with scholars based in United States, Sweden and United Kingdom. Julie Locklear's co-authors include Amy Grogg, Chris M Kozma, Peter J. Weiden, Henrik Svedsäter, Michael Eaddy, Jennifer Priaulx, Dennis A. Revicki, Björn Paulsson, Kathleen W. Wyrwich and Carolin Miltenburger and has published in prestigious journals such as Neurology, Journal of Affective Disorders and The Journal of Clinical Psychiatry.

In The Last Decade

Julie Locklear

38 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients With Schizophrenia

2004 519 citations Peter J. Weiden, Chris M Kozma et al. Psychiatric Services profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julie Locklear United States	14	1.0k	356	170	150	144	38	1.4k
Michael J. Sernyak United States	26	1.3k 1.3×	305 0.9×	91 0.5×	184 1.2×	219 1.5×	58	1.9k
Teresa Díez Spain	12	806 0.8×	324 0.9×	117 0.7×	141 0.9×	104 0.7×	30	1.1k
Tim Lambert Australia	23	1.1k 1.1×	513 1.4×	113 0.7×	166 1.1×	146 1.0×	69	1.7k
Ruth Ross United States	24	940 0.9×	602 1.7×	88 0.5×	166 1.1×	135 0.9×	36	1.5k
Hélène Verdoux France	17	872 0.9×	299 0.8×	229 1.3×	139 0.9×	99 0.7×	64	1.5k
Timothy Peters-Strickland United States	16	680 0.7×	173 0.5×	76 0.4×	44 0.3×	93 0.6×	43	893
Carmine Munizza Italy	16	484 0.5×	384 1.1×	245 1.4×	305 2.0×	348 2.4×	30	1.3k
Steven P. Shon United States	15	977 1.0×	277 0.8×	231 1.4×	220 1.5×	480 3.3×	18	1.5k
Cecilia Huang United States	17	1.1k 1.1×	451 1.3×	64 0.4×	272 1.8×	97 0.7×	26	1.8k
Scott Bull United States	14	794 0.8×	364 1.0×	126 0.7×	247 1.6×	291 2.0×	29	1.5k

Countries citing papers authored by Julie Locklear

Since Specialization

Citations

This map shows the geographic impact of Julie Locklear's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Locklear with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Locklear more than expected).

Fields of papers citing papers by Julie Locklear

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Locklear. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Locklear. The network helps show where Julie Locklear may publish in the future.

Co-authorship network of co-authors of Julie Locklear

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Locklear. A scholar is included among the top collaborators of Julie Locklear based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Locklear. Julie Locklear is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mannix, Sally, Mariam Hassan, Raj Tummala, et al.. (2015). Content validity of the Sheehan Irritability Scale in patients with major depressive disorder. International Clinical Psychopharmacology. 31(2). 110–117. 3 indexed citations

Khan, Sajjad, Dennis A. Revicki, Mariam Hassan, et al.. (2015). Assessing the Reliability and Validity of the Sheehan Irritability Scale in Patients With Major Depressive Disorder. The Journal of Clinical Psychiatry. 77(8). 1080–1086. 6 indexed citations

DiBonaventura, Marco, et al.. (2014). Economic and humanistic burden of illness in generalized anxiety disorder: an analysis of patient survey data in Europe. ClinicoEconomics and Outcomes Research. 6. 151–151. 20 indexed citations

Clayton, Anita H., Julie Locklear, Henrik Svedsäter, & Roger S. McIntyre. (2013). Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate. CNS Spectrums. 19(2). 182–196. 3 indexed citations

Locklear, Julie, Henrik Svedsäter, Catherine Datto, & Jean Endicott. (2013). Effects of once-daily extended release quetiapine fumarate (quetiapine XR) on quality of life and sleep in elderly patients with major depressive disorder. Journal of Affective Disorders. 149(1-3). 189–195. 13 indexed citations

Thase, Michael E., Stuart Montgomery, George I. Papakostas, et al.. (2013). Quetiapine XR monotherapy in major depressive disorder. International Clinical Psychopharmacology. 28(3). 113–120. 5 indexed citations

Sheehan, David V., Julie Locklear, Henrik Svedsäter, & Catherine Datto. (2012). Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate. International Clinical Psychopharmacology. 27(5). 239–248. 8 indexed citations

Ekman, Mattias, Peter Lindgren, Carolin Miltenburger, et al.. (2012). Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode. PharmacoEconomics. 30(6). 513–530. 16 indexed citations

Lasch, Kathryn, et al.. (2012). Development and content validity of a patient reported outcomes measure to assess symptoms of major depressive disorder. BMC Psychiatry. 12(1). 34–34. 14 indexed citations

10.

Locklear, Julie, et al.. (2011). PMH71 The Impact of Once-Daily Extended-Release Quetiapine Fumarate (Quetiapine XR) on Length and Costs of Hospitalisation of Patients with Schizophrenia or Bipolar Disorder. Value in Health. 14(7). A299–A299. 2 indexed citations

11.

Vieta, Eduard, Julie Locklear, Oliver Günther, et al.. (2010). Treatment Options for Bipolar Depression. Journal of Clinical Psychopharmacology. 30(5). 579–590. 94 indexed citations

12.

DiBonaventura, Marco, et al.. (2010). PMH16 THE ECONOMIC AND HUMANISTIC BURDEN OF ILLNESS IN GENERALISED ANXIETY DISORDER (GAD): A RETROSPECTIVE DATABASE ANALYSIS IN EUROPE. Value in Health. 13(7). A448–A448. 1 indexed citations

13.

Järbrink, Krister, Noémi Kreif, Ágnes Benedict, & Julie Locklear. (2009). Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia. Current Medical Research and Opinion. 25(3). 709–716. 9 indexed citations

14.

Locklear, Julie, et al.. (2009). A systematic review of the evidence of the burden of bipolar disorder in Europe. Clinical Practice and Epidemiology in Mental Health. 5(1). 3–3. 116 indexed citations

15.

Knapp, Martín, Julie Locklear, & Krister Järbrink. (2009). Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER. Current Medical Research and Opinion. 25(7). 1593–1603. 9 indexed citations

16.

Järbrink, Krister, et al.. (2009). P.3.e.019 The impact of once-daily quetiapine fumarate on length of hospitalisation in patients with mental illness. European Neuropsychopharmacology. 19. S578–S578. 1 indexed citations

17.

Lasser, Robert, Cynthia A. Bossie, Young Zhu, Julie Locklear, & John M. Kane. (2007). Long-Acting Risperidone in Young Adults with Early Schizophrenia or Schizoaffective Illness. Annals of Clinical Psychiatry. 19(2). 65–71. 19 indexed citations

18.

Edwards, Natalie C., Julie Locklear, Marcia F.T. Rupnow, & Ronald J. Diamond. (2005). Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. PharmacoEconomics. 23(S1). 75–89. 60 indexed citations

19.

Eaddy, Michael, Amy Grogg, & Julie Locklear. (2005). Assessment of compliance with antipsychotic treatmentand resource utilization in a medicaid population. Clinical Therapeutics. 27(2). 263–272. 89 indexed citations

20.

Weiden, Peter J., Chris M Kozma, Amy Grogg, & Julie Locklear. (2004). Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients With Schizophrenia. Psychiatric Services. 55(8). 886–891. 519 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact